The expression of myeloperoxidase (MPO) was studied in 100 cases of acute leukaemia (83 with acute myeloid leukaemia (AML) and 17 acute lymphoblastic leukaemia (ALL)) by both a conventional cytochemical method and the immunocytochemical antiperoxidase (APAAP) technique using the monoclonal antibody MPO7. In each case the staining was evaluated by light microscopical examination (percentage of positive cells). Of the 83 cases of AML, 78 (93-9%) were positive for MPO7 compared with 70 (84-3%) by cytochemistry. Antibodies against the myeloid markers CD13 and CD33 were positive in 71 (85'5%) and 70 (84-3%) cases, respectively. Importantly, all cases of ALL were negative for both MPO7 and cytochemical MPO staining even when they were positive for CD13 and CD33. These results indicate that the antimyeloperoxidase antibody MPO7 is the most sensitive and specific reagent for the diagnosis of AML and should therefore be included in routine immunophenotyping panels. Five (6%) cases of AML were negative for MP07 while 13 (15 6%) cases were negative 847
Five (6%) cases of AML were negative for MP07 while 13 (15 6%) cases were negative 12 All cases of ALL were negative for myeloperoxidase both by MPO7 and cytochemistry, confirming the enzyme specificity, though this observation was based on a relatively small number of cases and should be confirmed using larger numbers. This degree of specificity was not found with other "myeloid" antibodies as, for example, over half the cases of ALL reacted with anti-CD 13. The greater incidence of "lineage promiscuity" in this study, compared with that reported previously,'3 may reflect the small number of cases of ALL studied and the fact that both centres receive a disproportionate number of diagnostically difficult cases. It is not explained by our definition of positivity as the results are not significantly changed if this is increased from 10%, to 20% or greater.
These results confirm those of a recently published study which used an indirect immunofluorescence technique and an inhouse anti-MPO.'4 We suggest, therefore, that MPO7, in conjunction with the APAAP technique, which permits individual cell identification, is more sensitive than alternative anti-myeloid antibodies and standard cytochemistry.'
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